Abcam, ab257775, Human UBE2C knockout HeLa cell lysate

Size: 1Kit
UBE2C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-UBE2C, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UBE2C also known as ubiquitin-conjugating enzyme E2C or UBCH10 is an enzyme that plays a role in the ubiquitination process. Its molecular mass is approximately 20 kDa. UBE2C is an E2 ubiquitin-conjugating enzyme actively involved in marking proteins for degradation through the ubiquitin-proteasome system. It facilitates the transfer of ubiquitin to target proteins cooperating with E3 ligases. UBE2C shows expression in various tissues with high levels observed in proliferating cells such as those found in tumors.
Biological function summary
UBE2C is involved in cell cycle regulation by targeting specific proteins for ubiquitination and degradation. It collaborates with the anaphase-promoting complex/cyclosome (APC/C) an important E3 ligase complex ensuring the proper progression of the cell cycle especially during the metaphase-anaphase transition. Through this action UBE2C aids in maintaining genomic stability by preventing the accumulation of proteins that can interfere with cell division.
Pathways
The role of UBE2C is integral in the cell cycle and ubiquitin-proteasome pathways. The enzyme participates in the proper execution of the metaphase-anaphase transition and degradation of cell cycle regulators like cyclin B. UBE2C interacts with proteins such as CDC20 a co-activator of APC/C to ensure accurate coordination of cell division events. Its function in the ubiquitin-proteasome pathway emphasizes its role in maintaining protein homeostasis.
UBE2C's dysfunction or overexpression associates with cancer development and progression. Overexpression of UBE2C has been observed in various cancers including breast cancer and prostate cancer and may contribute to tumorigenesis by disrupting cell cycle control. UBE2C can interact with oncoproteins such as MYC further linking its dysregulation to cancer pathways. Understanding the relationships between UBE2C and cancer may offer insights into therapeutic targets for tumor treatment.